Maryland is currently home to 2687 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
NCT05687110
Recruiting
This phase I trial tests the safety, side effects, and best dose of novobiocin in treating cancer patients with alterations in deoxyribonucleic acid (DNA) repair genes. Novobiocin is an antibiotic that blocks the activity of a protein called DNA polymerase theta, which helps repair DNA that has become damaged as cells grow and divide. Cancer cells that cannot repair their damaged DNA die. This medication may help shrink or stabilize cancer with a mutation in DNA repair genes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
NCT05675930
Recruiting
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
Gender:
ALL
Ages:
4 years and above
Trial Updated:
05/07/2025
Locations: National Institute of Health (Data Collection AND Specimen Analysis), Bethesda, Maryland
Conditions: Graft-Versus-Host Disease, GVHD, Undefined
Register for Updates
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT05498272
Recruiting
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic select HRR alterations. Germline and somatic mutation testing will be performed as part of commercially available CLIA assays and will be validated on a uniform platform centrally all... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Register for Updates
Oral Cannabidiol for Tobacco Cessation
NCT05445804
Recruiting
Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/07/2025
Locations: Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland
Conditions: Tobacco Use, Tobacco Smoking, Tobacco Dependence, Tobacco Use Disorder, Tobacco Use Cessation
Register for Updates
Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea
NCT05052216
Recruiting
Background: Obstructive sleep apnea (OSA) occurs when the blockage of the airway causes a person to stop breathing involuntarily for 10 seconds or more throughout the night during sleep. Pediatric OSA can be especially concerning and can have long-term effects. Researchers want to see how a monitoring device called near-infrared spectroscopy (NIRS) compares with the traditional techniques used in children s sleep studies. Objective: To learn about oxygen levels in the brain and limbs in child... Read More
Gender:
ALL
Ages:
Between 3 years and 12 years
Trial Updated:
05/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pediatric Obstructive Sleep Apnea
Register for Updates
Economic Incentives and vDOT for Latent Tuberculosis Infection
NCT05022862
Recruiting
The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Baltimore City Health Department, and Baltimore metropolitan area clinics and health departments, Baltimore, Maryland
Conditions: Latent Tuberculosis
Register for Updates
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT04915183
Recruiting
Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objective: To find out if atorvastatin reduces hearing loss in people treated with cisplatin and radiation. Eligibility: People ages 18 and older with squamous cell carcinoma of the head and neck who will undergo treatment with cisplatin-based chemotherapy and ra... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/07/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Hearing Loss, Head and Neck Cancer
Register for Updates
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
NCT04678154
Recruiting
The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/07/2025
Locations: University of Maryland , MD Department of Orthopaedics, Baltimore, Maryland
Conditions: Post Operative Surgical Site Infection
Register for Updates
Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA
NCT04597008
Recruiting
The overall objective is to compare the effect of Vancomycin and Tobramycin powder combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation infections of tibial plateau and tibial pilon fractures at high risk of infection (collectively considered the "study injuries").
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/07/2025
Locations: University of Maryland Shock Trauma Center, Baltimore, Maryland
Conditions: Post Operative Surgical Site Infection
Register for Updates
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
NCT04554914
Recruiting
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Gender:
ALL
Ages:
All
Trial Updated:
05/07/2025
Locations: University of Maryland Medical Center (Adults only), Baltimore, Maryland
Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
Register for Updates
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597
Recruiting
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: The Center for Cancer and Blood Disorders (CCBD), Bethesda, Maryland
Conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
Register for Updates
Human Upper Extremity Allotransplantation: F/U Protocol
NCT03400345
Recruiting
Upper extremity allotransplantation is a new procedure which is becoming more common in the United States. Ongoing data collection for research purposes is vital to the long-term assessment as to the safety of the procedure and accompanying immunosuppression protocol, as well as quantifying patient outcomes and changes in quality of life. For these reasons, The Johns Hopkins Hand/Arm Transplantation Team is interested in enrolling transplanted patients in a follow-up protocol to continue collect... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/07/2025
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Amputation, Traumatic, Wounds and Injury, Hand Injuries
Register for Updates